Description du projet
Un nouveau dispositif destiné à atténuer les symptômes de l’hyperplasie bénigne de la prostate
Basée à Dublin, la société ProVerum Limited se concentre sur le développement de nouvelles technologies mini-invasives pour traiter l’hyperplasie bénigne de la prostate (HBP), une affection courante chez les hommes âgés entraînant des difficultés à uriner. Le projet ProVee, financé par l’UE, élabore un implant qui atténue les symptômes causés par cette maladie. Il soulage le patient grâce à une procédure ambulatoire de cinq minutes en implantant le dispositif ProVee sous anesthésie locale. Une fois implanté, le dispositif ProVee est bien toléré. En outre, les premières données suggèrent un excellent profil de sécurité. L’appareil est conçu pour améliorer considérablement la qualité de vie des personnes touchées par l’HBP.
Objectif
ProVerum Limited, an innovative Dublin based SME focused on the development of novel minimally invasive technologies to treat Benign Prostatic Hyperplasia, a common condition in older men causing difficulty with urination with a profound deterioration in quality of life.
The company’s first product (called ‘ProVee’) is a self-expanding implant that alleviates the symptoms caused by BPH.
Benign Prostatic Hyperplasia is an enlargement of the prostate gland which causes impingement upon the urethra, the tube which eliminates urine from the bladder. Sufferers present with Lower Urinary Tract Symptoms (LUTS), including difficulty in urinating and urinary retention causing a frequent urge to urinate day and night and having a profound effect on quality of life.
BPH is extremely common in men and is the number 1 reason men visit their urologist both in the US and Europe, with 19M men treated for BPH each year in Europe and 12M men treated for BPH each year in the US.
ProVee offers the patient relief from BPH symptoms through a simple, minimally invasive, 5-minute, outpatient procedure to implant the ProVee device under local anaesthetic. Once implanted, the ProVee addresses urinary problems, is well tolerated and early data suggests has an excellent safety profile
Following this H2020 EIC Accelerator project, the technology will be at TRL 8, with clinical evidence from a 50 Patient CE Trial, CE Mark approval and further commercialisation will enable the treatment of 70,000 patients in Year 4 post project.
Champ scientifique
Programme(s)
Régime de financement
SME - SME instrumentCoordinateur
DUBLIN 8 Dublin
Irlande
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.